In-vivo delivery of therapeutic proteins by genetically-modified cells: comparison of organoids and human serum albumin alginate-coated beads
- 1 December 1999
- journal article
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 53 (10) , 471-483
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- The in vivo delivery of heterologous proteins by microencapsulated recombinant cellsTrends in Biotechnology, 1999
- Immunoisolation: at a turning pointImmunology Today, 1997
- Long-term delivery of a lysosomal enzyme by genetically modified fibroblasts in dogsNature Medicine, 1995
- Correction of the Growth Defect in Dwarf Mice with Nonautologous Microencapsulated Myoblasts—An Alternate Approach to Somatic Gene TherapyHuman Gene Therapy, 1995
- Retrovirus-mediated transfer of the erythropoietin gene in hematopoietic cells improves the erythrocyte phenotype in murine beta- thalassemiaBlood, 1994
- CONTINUOUS SYSTEMIC SECRETION OF A LYSOSOMAL ENZYME BY GENETICALLY MODIFIED MOUSE SKIN FIBROBLASTSTransplantation, 1993
- Microencapsulation of recombinant cells: a new delivery system for gene therapyThe FASEB Journal, 1993
- Correction of lysosomal storage in the liver and spleen of MPS VII mice by implantation of genetically modified skin fibroblastsNature Genetics, 1993
- Trial of recombinant human erythropoietin: three patients with thalassemia intermedia [letter]Blood, 1992
- Improvement of mouse beta-thalassemia by recombinant human erythropoietinBlood, 1991